Bactiguard (BACTI) Q1 2025 earnings summary

Executive summary

• Achieved fourth consecutive quarter of positive EBITDA, with Q1 2025 EBITDA at SEK 9.4 million and revenues of SEK 62.7 million, up 6.7% year-over-year.

• Wound management portfolio revenues surged over 50% to SEK 19.2 million, driven by Hydrocyn Aqua sales.

• Updated strategic and financial targets for 2030: at least SEK 600 million in revenue, SEK 200 million in EBITDA, and over 10 application areas in partnerships.

• Strong partnerships, especially with BD, continue to drive license revenue growth and market expansion.

• Net loss for the period was SEK 4.7 million, improved from SEK 9.9 million loss last year.

Financial highlights

• Q1 2025 revenues reached SEK 62.7 million, a 7% increase year-over-year; net sales at SEK 59.1 million, up 9.5%.

• Licensed business revenue grew 12% to SEK 39.3 million, with BD contributing SEK 32.2 million (up 15.1%).

• Operating costs decreased by 13% to SEK 42 million, reflecting SEK 7 million in net savings.

• EBITDA margin improved to 15.0%, with rolling 12-month EBITDA at SEK 28.9 million.

• Cash position at quarter-end was SEK 46.8 million, mainly due to SEK 51 million voluntary loan repayment.

Outlook and guidance

• Focus remains on profitable growth, expanding partnerships, and new market entry, with a scalable business model and operational leverage expected to deliver value beyond 2030.

• Updated 2030 targets: at least SEK 600 million in revenue, SEK 200 million in EBITDA, and 10 application areas in partnerships.

• Wound Management expected to maintain double-digit profitability.

• Focus sharpened on Orthopedics, Cardiology, Neurology, Urology, and Vascular Access.

• No direct impact from U.S. tariffs, but significant U.S. dollar exposure could affect results if the dollar weakens.